Tumor Mutation Burden (TMB) is Associated with Improved Efficacy of Atezolizumab in 1L and 2L+NSCLC Patients

被引：77
|
作者：
Kowanetz, Marcin [1 ]
Zou, Wei [1 ]
Shames, David [1 ]
Cummings, Craig [1 ]
Rizvi, Naiyer [2 ]
Spira, Alexander [3 ,4 ]
Frampton, Garrett [5 ]
Leveque, Vincent [1 ]
Flynn, Susan [1 ]
Mocci, Simonetta [1 ]
Shankar, Geetha [1 ]
Funke, Roel [1 ]
Ballinger, Marcus [1 ]
Waterkamp, Daniel [1 ]
Chen, Daniel [1 ]
Sandler, Alan [1 ]
Hampton, Garret [1 ]
Amler, Lukas [1 ]
Hegde, Priti [1 ]
Hellmann, Matthew [6 ]
机构：
[1] Genentech Inc, San Francisco, CA 94080 USA
[2] Columbia Univ, New York, NY USA
[3] US Oncol Res, The Woodlands, TX USA
[4] Virginia Canc Specialists Res Inst, Fairfax, VA USA
[5] Fdn Med, Cambridge, MA USA
[6] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期
关键词：
Immunotherapy; mutational load; NSCLC; Biomarkers;
D O I：
10.1016/j.jtho.2016.11.343
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OA20.01
引用
下载
收藏
页码：S321 / S322
页数：2
相关论文
共 50 条
  • [41] Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC
    Herbst, Roy S.
    Giaccone, Giuseppe
    de Marinis, Filippo
    Reinmuth, Niels
    Vergnenegre, Alain
    Barrios, Carlos H.
    Morise, Masahiro
    Felip, Enriqueta
    Andric, Zoran
    Geater, Sarayut
    Ozguroglu, Mustafa
    Zou, Wei
    Sandler, Alan
    Enquist, Ida
    Komatsubara, Kimberly
    Deng, Yu
    Kuriki, Hiroshi
    Wen, Xiaohui
    McCleland, Mark
    Mocci, Simonetta
    Jassem, Jacek
    Spigel, David R.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (14): : 1328 - 1339
  • [42] A Phase (Ph) III clinical program: 1L atezolizumab (atezo) plus chemotherapy (chemo) in chemo-naive advanced NSCLC
    Mok, T. S. K.
    Jotte, R. M.
    Cappuzzo, F.
    Reck, M.
    Papadimitrakopoulou, V.
    West, H. J.
    Sandler, A.
    Mocci, S.
    Coleman, S.
    Asakawa, T.
    Socinski, M. A.
    ANNALS OF ONCOLOGY, 2016, 27
  • [43] Tremelimumab (T) plus durvalumab (D) plus chemotherapy (CT) in 1L metastatic NSCLC: Outcomes by blood tumor mutational burden (bTMB) in POSEIDON
    Peters, Solange
    Madison, Hisani
    Oliner, Kelly
    L'Hernault, Anne
    Ratcliffe, Marianne
    Barrett, Karen
    Shi, Xiaojin
    Garon, Edward B.
    Mok, Tony
    Johnson, Melissa L.
    CANCER RESEARCH, 2023, 83 (08)
  • [44] PD-L1, tumor mutational burden (TMB) and long-term survival in patients with non-small cell lung cancer (NSCLC) and brain metastases.
    Adib, Elio
    Nassar, Amin
    Kwiatkowski, David J.
    Aizer, Ayal
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [45] Antitumor activity of dostarlimab by PD-L1 and tumor mutation burden (TMB) in patients (pts) with mismatch repair deficient and proficient (dMMR and MMRp) tumors in the GARNET trial
    Andre, Thierry
    Banerjee, Susana
    Berton, Dominique
    Ellard, Susan L.
    Jimenez, Begona
    Samouelian, Vanessa
    Gilbert, Lucy
    Boni, Valentina
    Han, Xinwei
    Antony, Grace
    Veneris, Jennifer
    Oaknin., Ana
    CANCER RESEARCH, 2022, 82 (12)
  • [46] Antitumor activity of dostarlimab by PD-L1 and tumor mutation burden (TMB) in patients (pts) with mismatch repair deficient and proficient (dMMR and MMRp) tumors in the GARNET trial
    Vogel, Arndt
    Andre, Thierry
    Banerjee, Susana
    Berton, Dominique
    Ellard, Susan L.
    Jimenez, Begona
    Samouelian, Vanessa
    Gilbert, Lucy
    Boni, Valentina
    Han, Xinwei
    Antony, Grace
    Veneris, Jennifer
    Oaknin, Ana
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 17 - 17
  • [47] Incidence of high tumor mutation burden (TMB) and PD-L1 positivity in breast cancers and potential response to immune checkpoint inhibitors (ICPIs)
    Sokol, Ethan
    Albacker, Lee
    Soyano, Aixa
    Parrondo, Ricardo
    Ernst, Brenda
    Gabriel, Emmanuel
    Frampton, Garrett
    Ross, Jeffrey
    Ali, Siraj
    Chung, Jon
    Chumsri, Saranya
    CANCER RESEARCH, 2019, 79 (13)
  • [48] Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1)
    Kowanetz, Marcin
    Zou, Wei
    Gettinger, Scott N.
    Koeppen, Hartmut
    Kockx, Mark
    Schmid, Peter
    Kadel, Edward E., III
    Wistuba, Ignacio
    Chaft, Jamie
    Rizvi, Naiyer A.
    Spigel, David R.
    Spira, Alexander
    Hirsch, Fred R.
    Cohen, Victor
    Smith, Dustin
    Boyd, Zach
    Miley, Natasha
    Flynn, Susan
    Leveque, Vincent
    Shames, David S.
    Ballinger, Marcus
    Mocci, Simonetta
    Shankar, Geetha
    Funke, Roel
    Hampton, Garret
    Sandler, Alan
    Amler, Lukas
    Mellman, Ira
    Chen, Daniel S.
    Hegde, Priti S.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2018, 115 (43) : E10119 - E10126
  • [49] Clinical Benefits of First-Line (1L) Cemiplimab Monotherapy by PD-L1 Expression Levels in Patients With Advanced NSCLC
    Kilickap, S.
    Sezer, A.
    Gumus, M.
    Bondarenko, I.
    Ozguroglu, M.
    Gogishvili, M.
    Turk, H. M.
    Cicin, I.
    Bentsion, D.
    Gladkov, O.
    Clingan, P.
    Sriuranpong, V.
    Rizvi, N.
    Li, S.
    Lee, S.
    Makharadze, T.
    Paydas, S.
    Nechaeva, M.
    Seebach, F.
    Weinreich, D. M.
    Yancopoulos, G. D.
    Gullo, G.
    Lowy, I.
    Rietschel, P.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S101 - S101
  • [50] A Phase 3b Study of 1L Savolitinib in Patients with Locally Advanced or Metastatic NSCLC Harboring MET Exon 14 Mutation
    Lu, S.
    Yu, Y.
    Guo, Q.
    Li, Y.
    Zhong, D.
    Gu, L.
    Fang, J.
    Han, S.
    Pan, P.
    Deng, P.
    Liu, B.
    Wang, M.
    Wu, H.
    Gao, F.
    Lin, W.
    Li, J.
    Lv, D.
    He, S.
    Liu, Z.
    Pan, C.
    Li, J.
    Tian, Y.
    Yang, N.
    Zhang, Y.
    Liu, C.
    Zhu, X.
    Song, Q.
    Yu, J.
    Fan, S.
    Ren, Y.
    Shi, M.
    Su, W.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S92 - S93
12345